DCK and myeloid sarcoma: Cladribine preferentially depletes lymphocytes due to their high DCK:5′NT ratio and mediates its therapeutic effect in MS patients by accumulating within lymphocytes to disrupt cellular metabolism and DNA production, causing apoptosis [37].